Small Cell Lung Cancer Spotlight

It is important to have a multidisciplinary approach in the treatment of patients with small cell lung cancer, according to Jason Porter, MD, medical oncologist and hematologist, West Cancer Center and Research Institute, Memphis, Tennessee. This team approach allows for early intervention with signs of relapse or progression.

Jason Porter, MD, medical oncologist and hematologist, West Cancer Center and Research Institute, Memphis, Tennessee, defines small cell lung cancer and the risk factors associated with it. With smoking as a major risk factor, diagnosis for small cell lung cancer is rare compared with non–small cell lung cancer and varies widely by region in the United States.

Angel Qin, MD, clinical assistant professor of medicine at the University of Michigan, discusses the need for more clinical trials in small cell lung cancer and for more patients to qualify for trials.

Apar Kishor Ganti, MD, who chairs the Small Cell Lung Cancer Committee of the National Comprehensive Cancer Network, spoke with The American Journal of Managed Care® (AJMC®) about current issues in small cell lung cancer, including the need to include patients in clinical trials who are more representative of those in clinical practice.

Ryan Haumschild PharmD, MS, MBA, director of Pharmacy Services at Emory Healthcare and Winship Cancer Institute, spoke with AJMC® about health care resource utilization and clinical decision support in the care of patients with small cell lung cancer (SCLC).

Michael Shafique, MD, an assistant professor of thoracic oncology at Moffitt Cancer Center, spoke with The American Journal of Managed Care® about efforts to characterize small cell lung cancer (SCLC) into subtypes as well as the process for treatment selection in this disease.

Anne Chiang, MD, PhD, an associate professor of medicine in the Section of Medical Oncology at Yale School of Medicine, specializes in thoracic oncology, with a background in translational research in metastasis. Chiang spoke with The American Journal of Managed Care® (AJMC®) about monitoring patients with SCLC, developing treatments for patients who relapse, and the importance of patient-reported outcomes (PROs).

Martin J. Edelman, MD, chair and professor, Department of Hematology/Oncology, and Deputy Cancer Center Director for Clinical Research, Fox Chase Cancer Center, Philadelphia, discusses barriers to clinical trial enrollment for patients with small cell lung cancer.

Jacob Sands, MD, who leads the small cell lung cancer research program at Dana-Farber Cancer Institute, speaks with The American Journal of Managed Care (AJMC®) about the need for more patients who meet the criteria for lung screening to catch cancer before it reaches an advanced stage.

Zhonglin Hao, MD, PhD, of the Markey Cancer Center at the University of Kentucky, answers questions about recently approved therapies in small cell lung cancer (SCLC) and current trials examining new treatment options.

Tingting Tan, MD, PhD, a medical oncologist and lung cancer specialist at City of Hope, is an expert in molecular signaling pathways in tumor development and the mechanisms of chemotherapy resistance. She discussed how the treatment landscape in small cell lung cancer has shifted in the past 5 years, offering much more hope for patients.

David J. Reeves, PharmD, BCOP, of Butler University discusses encouraging results from a recent trial, along with safety questions about the types of patients who weren't studied but are likely to have small cell lung cancer.

The chief of medical oncology and hematology at Bryn Mawr Hospital and associate principal investigator for Main Line Health's NCI Community Oncology Research Program discusses therapeutic advances along with ongoing challenges in enrolling patients with small cell lung cancer (SCLC) in clinical trials.

Apar Kishor Ganti, MD, chair of the National Comprehensive Cancer Network Guidelines panel in small cell lung cancer, explains the thinking behind several new recommendations.

Davey Daniel, MD, an oncologist with Tennessee Oncology in Chattanooga, spoke with The American Journal of Managed Care® (AJMC®) about the withdrawal of indications in small cell lung cancer (SCLC) for the PD-1 inhibitors pembrolizumab and nivolumab.

Martin J. Edelman, MD, chair of the Department of Hematology/Oncology and associate director for Translational Research at the Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses the the nuances of rescinded indications in small-cell lung cancer.

Kathryn Gold, MD, medical oncologist and associate professor of medicine at UC San Diego, who is a member of the NCCN guidelines panel for small-cell lung cancer, gives insight into the guidelines and the importance of frequent updates.